<p><strong>金醫療國際有限公司</strong>（NASDAQ:ZJYL）的股價在過去一個月表現非常糟糕，下降了 33%。最近的下跌使得過去一年對股東來説是災難性的，他們在此期間的損失達到了 83%。</p>
<p>即使在如此大幅的價格下跌之後，金醫療國際目前可能仍在發出非常悲觀的信號，其市盈率（&#34;P/E&#34;）為 38 倍，因為美國幾乎一半的公司市盈率低於 18 倍，甚至低於 11 倍的市盈率也並不罕見。不過，僅僅根據市盈率來判斷並不明智，因為可能有解釋説明其如此高的原因。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>例如，考慮到金醫療國際最近的財務表現不佳，其收益一直在下降。許多人可能仍然期望該公司在未來一段時間內表現優於大多數其他公司，這使得市盈率沒有崩潰。你真的希望如此，否則你將為沒有特別理由的高價格買單。</p>
<p>查看我們對金醫療國際的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1760091693748?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1760091693748"/></p>
<p>NasdaqCM:ZJYL 市盈率與行業比較 2025 年 10 月 10 日</p>
<p>雖然沒有關於金醫療國際的分析師預測，但請查看這個 <strong>免費的</strong> 數據豐富的可視化，看看該公司在收益、收入和現金流方面的表現。</p>
<h2>金醫療國際的增長趨勢如何？</h2>
<p>金醫療國際的市盈率對於一家預計將實現強勁增長的公司來説是典型的，重要的是，它的表現將遠超市場。</p>
<p>回顧過去一年，該公司的淨利潤下降了 39%。過去三年的表現也不佳，因為該公司的每股收益總共下降了 99%。因此，股東們對中期收益增長率感到沮喪。</p>
<p>將這一中期收益軌跡與市場對未來一年 15% 的擴張預測進行比較，顯示出這並不樂觀。</p>
<p>根據這些信息，我們發現金醫療國際的市盈率高於市場，這令人擔憂。顯然，許多投資者對該公司的看法比近期的表現要樂觀得多，並且不願意以任何價格出售他們的股票。如果市盈率降至與近期負增長率更為一致的水平，現有股東很可能會面臨未來的失望。</p>
<h2>關鍵要點</h2>
<p>金醫療國際的股票可能已經回落，但其市盈率仍然高企。我們認為市盈率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
<p>我們對金醫療國際的審查顯示，其中期收益的下降並沒有像我們預測的那樣對其高市盈率產生太大影響，因為市場預計將增長。當我們看到收益下滑並且表現不及市場預期時，我們懷疑股價面臨下跌風險，從而使高市盈率降低。如果近期中期收益趨勢持續下去，將使股東的投資面臨重大風險，並使潛在投資者面臨支付過高溢價的危險。</p>
<p>還有其他重要的風險因素需要考慮，我們發現 <strong>金醫療國際的 4 個警告信號</strong>（其中 1 個讓我們感到不安！）在投資前你應該瞭解。</p>
<p>當然，<strong>你可能會通過尋找一些優秀的候選者找到一個絕佳的投資機會。</strong> 所以請查看這個 <strong>免費的</strong> 強勁增長記錄的公司名單，它們的市盈率較低。</p>

中進醫療

<p>中進醫療國際有限公司（NASDAQ:ZJYL）的股價在過去一個月內暴跌了 33%，導致股東在過去一年中損失了 83%。儘管出現這種下滑，該公司的市盈率仍高達 38 倍，顯示出投資者的樂觀情緒。然而，隨着收益下降 39% 以及每股收益在三年內下降 99%，人們對這種估值的可持續性產生了擔憂。分析師警告稱，如果收益繼續下降，股價可能會進一步下跌，這對當前和潛在的投資者構成風險</p>

<p>The <strong>Jin Medical International Ltd.</strong> (NASDAQ:ZJYL) share price has fared very poorly over the last month, falling by a substantial 33%. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 83% loss during that time.</p>
<div class="lb-trans"><p><strong>金醫療國際有限公司</strong>（NASDAQ:ZJYL）的股價在過去一個月表現非常糟糕，下降了 33%。最近的下跌使得過去一年對股東來説是災難性的，他們在此期間的損失達到了 83%。</p>
</div><p>Even after such a large drop in price, Jin Medical International may still be sending very bearish signals at the moment with a price-to-earnings (or &#34;P/E&#34;) ratio of 38x, since almost half of all companies in the United States have P/E ratios under 18x and even P/E's lower than 11x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.</p>
<div class="lb-trans"><p>即使在如此大幅的價格下跌之後，金醫療國際目前可能仍在發出非常悲觀的信號，其市盈率（&#34;P/E&#34;）為 38 倍，因為美國幾乎一半的公司市盈率低於 18 倍，甚至低於 11 倍的市盈率也並不罕見。不過，僅僅根據市盈率來判斷並不明智，因為可能有解釋説明其如此高的原因。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>For example, consider that Jin Medical International's financial performance has been poor lately as its earnings have been in decline. It might be that many expect the company to still outplay most other companies over the coming period, which has kept the P/E from collapsing. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.</p>
<div class="lb-trans"><p>例如，考慮到金醫療國際最近的財務表現不佳，其收益一直在下降。許多人可能仍然期望該公司在未來一段時間內表現優於大多數其他公司，這使得市盈率沒有崩潰。你真的希望如此，否則你將為沒有特別理由的高價格買單。</p>
</div><p>See our latest analysis for Jin Medical International</p>
<div class="lb-trans"><p>查看我們對金醫療國際的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1760091693748" alt="" original-src="https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1760091693748"/></p>
<p>NasdaqCM:ZJYL Price to Earnings Ratio vs Industry October 10th 2025</p>
<div class="lb-trans"><p>NasdaqCM:ZJYL 市盈率與行業比較 2025 年 10 月 10 日</p>
</div><p>Although there are no analyst estimates available for Jin Medical International, take a look at this <strong>free</strong> data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>雖然沒有關於金醫療國際的分析師預測，但請查看這個 <strong>免費的</strong> 數據豐富的可視化，看看該公司在收益、收入和現金流方面的表現。</p>
</div><h2>How Is Jin Medical International's Growth Trending?</h2>
<div class="lb-trans"><h2>金醫療國際的增長趨勢如何？</h2>
</div><p>Jin Medical International's P/E ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the market.</p>
<div class="lb-trans"><p>金醫療國際的市盈率對於一家預計將實現強勁增長的公司來説是典型的，重要的是，它的表現將遠超市場。</p>
</div><p>Retrospectively, the last year delivered a frustrating 39% decrease to the company's bottom line. The last three years don't look nice either as the company has shrunk EPS by 99% in aggregate. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.</p>
<div class="lb-trans"><p>回顧過去一年，該公司的淨利潤下降了 39%。過去三年的表現也不佳，因為該公司的每股收益總共下降了 99%。因此，股東們對中期收益增長率感到沮喪。</p>
</div><p>Weighing that medium-term earnings trajectory against the broader market's one-year forecast for expansion of 15% shows it's an unpleasant look.</p>
<div class="lb-trans"><p>將這一中期收益軌跡與市場對未來一年 15% 的擴張預測進行比較，顯示出這並不樂觀。</p>
</div><p>With this information, we find it concerning that Jin Medical International is trading at a P/E higher than the market. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. There's a very good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the recent negative growth rates.</p>
<div class="lb-trans"><p>根據這些信息，我們發現金醫療國際的市盈率高於市場，這令人擔憂。顯然，許多投資者對該公司的看法比近期的表現要樂觀得多，並且不願意以任何價格出售他們的股票。如果市盈率降至與近期負增長率更為一致的水平，現有股東很可能會面臨未來的失望。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><p>Jin Medical International's shares may have retreated, but its P/E is still flying high. We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>金醫療國際的股票可能已經回落，但其市盈率仍然高企。我們認為市盈率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
</div><p>Our examination of Jin Medical International revealed its shrinking earnings over the medium-term aren't impacting its high P/E anywhere near as much as we would have predicted, given the market is set to grow. When we see earnings heading backwards and underperforming the market forecasts, we suspect the share price is at risk of declining, sending the high P/E lower. If recent medium-term earnings trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.</p>
<div class="lb-trans"><p>我們對金醫療國際的審查顯示，其中期收益的下降並沒有像我們預測的那樣對其高市盈率產生太大影響，因為市場預計將增長。當我們看到收益下滑並且表現不及市場預期時，我們懷疑股價面臨下跌風險，從而使高市盈率降低。如果近期中期收益趨勢持續下去，將使股東的投資面臨重大風險，並使潛在投資者面臨支付過高溢價的危險。</p>
</div><p>There are also other vital risk factors to consider and we've discovered <strong>4 warning signs for Jin Medical International</strong> (1 doesn't sit too well with us!) that you should be aware of before investing here.</p>
<div class="lb-trans"><p>還有其他重要的風險因素需要考慮，我們發現 <strong>金醫療國際的 4 個警告信號</strong>（其中 1 個讓我們感到不安！）在投資前你應該瞭解。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking at a few good candidates.</strong> So take a peek at this <strong>free</strong> list of companies with a strong growth track record, trading on a low P/E.</p>
<div class="lb-trans"><p>當然，<strong>你可能會通過尋找一些優秀的候選者找到一個絕佳的投資機會。</strong> 所以請查看這個 <strong>免費的</strong> 強勁增長記錄的公司名單，它們的市盈率較低。</p>
</div>

由於中進醫療國際有限公司（NASDAQ:ZJYL）的股價下跌了 33%，一些股東正在尋求退出